カテゴリー： Market Monitor Global, 世界, 医療/バイオ

非チロシンキナーゼ阻害剤の世界市場見通し2023年-2029年

◆英語タイトル：Non-Tyrosine Kinase Inhibitors Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5814）

◆商品コード：MMG23JU5814
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：110
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Non-Tyrosine Kinase Inhibitors Market 調査レポートは次の情報を含め、グローバルにおけるの非チロシンキナーゼ阻害剤市場規模と予測を収録しています。・世界の非チロシンキナーゼ阻害剤市場：売上、2018年-2023年、2024年-2029年
・世界の非チロシンキナーゼ阻害剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の非チロシンキナーゼ阻害剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「mTOR阻害剤」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

非チロシンキナーゼ阻害剤のグローバル主要企業は、Roche、 Eli Lilly、 Novartis、 Array BioPharma、 Nerviano Medical Sciences、 Pfizer、 Merck KGaA、 Astex Pharmaceuticals、 Cyclacel Pharmaceuticals、 Daiichi Sankyo、 Onconova Therapeutics、 AstraZeneca、 GlaxoSmithKline (GSK)、 Carna Biosciences、 Celgene Corporation、 Eternity Bioscience、 Jasco Pharmaceuticalsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、非チロシンキナーゼ阻害剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の非チロシンキナーゼ阻害剤市場：タイプ別、2018年-2023年、2024年-2029年
世界の非チロシンキナーゼ阻害剤市場：タイプ別市場シェア、2022年
・mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤

世界の非チロシンキナーゼ阻害剤市場：用途別、2018年-2023年、2024年-2029年
世界の非チロシンキナーゼ阻害剤市場：用途別市場シェア、2022年
・肝臓がん、呼吸器がん、脳がん、その他

世界の非チロシンキナーゼ阻害剤市場：地域・国別、2018年-2023年、2024年-2029年
世界の非チロシンキナーゼ阻害剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における非チロシンキナーゼ阻害剤のグローバル売上、2018年-2023年
・主要企業における非チロシンキナーゼ阻害剤のグローバル売上シェア、2022年
・主要企業における非チロシンキナーゼ阻害剤のグローバル販売量、2018年-2023年
・主要企業における非チロシンキナーゼ阻害剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Roche、 Eli Lilly、 Novartis、 Array BioPharma、 Nerviano Medical Sciences、 Pfizer、 Merck KGaA、 Astex Pharmaceuticals、 Cyclacel Pharmaceuticals、 Daiichi Sankyo、 Onconova Therapeutics、 AstraZeneca、 GlaxoSmithKline (GSK)、 Carna Biosciences、 Celgene Corporation、 Eternity Bioscience、 Jasco Pharmaceuticals

*************************************************************

・調査・分析レポートの概要
非チロシンキナーゼ阻害剤市場の定義
市場セグメント
世界の非チロシンキナーゼ阻害剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の非チロシンキナーゼ阻害剤市場規模
世界の非チロシンキナーゼ阻害剤市場規模：2022年 VS 2029年
世界の非チロシンキナーゼ阻害剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの非チロシンキナーゼ阻害剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の非チロシンキナーゼ阻害剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤
非チロシンキナーゼ阻害剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：肝臓がん、呼吸器がん、脳がん、その他
非チロシンキナーゼ阻害剤の用途別グローバル売上・予測

・地域別市場分析
地域別非チロシンキナーゼ阻害剤市場規模 2022年と2029年
地域別非チロシンキナーゼ阻害剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Roche、 Eli Lilly、 Novartis、 Array BioPharma、 Nerviano Medical Sciences、 Pfizer、 Merck KGaA、 Astex Pharmaceuticals、 Cyclacel Pharmaceuticals、 Daiichi Sankyo、 Onconova Therapeutics、 AstraZeneca、 GlaxoSmithKline (GSK)、 Carna Biosciences、 Celgene Corporation、 Eternity Bioscience、 Jasco Pharmaceuticals
...

This report aims to provide a comprehensive presentation of the global market for Non-Tyrosine Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Tyrosine Kinase Inhibitors. This report contains market size and forecasts of Non-Tyrosine Kinase Inhibitors in global, including the following market information:
Global Non-Tyrosine Kinase Inhibitors Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Non-Tyrosine Kinase Inhibitors Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Non-Tyrosine Kinase Inhibitors companies in 2022 (%)
The global Non-Tyrosine Kinase Inhibitors market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
mTOR Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Tyrosine Kinase Inhibitors include Roche, Eli Lilly, Novartis, Array BioPharma, Nerviano Medical Sciences, Pfizer, Merck KGaA, Astex Pharmaceuticals and Cyclacel Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Tyrosine Kinase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Tyrosine Kinase Inhibitors Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Non-Tyrosine Kinase Inhibitors Market Segment Percentages, by Type, 2022 (%)
mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors
Global Non-Tyrosine Kinase Inhibitors Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Non-Tyrosine Kinase Inhibitors Market Segment Percentages, by Application, 2022 (%)
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Global Non-Tyrosine Kinase Inhibitors Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Tyrosine Kinase Inhibitors revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Non-Tyrosine Kinase Inhibitors revenues share in global market, 2022 (%)
Key companies Non-Tyrosine Kinase Inhibitors sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Non-Tyrosine Kinase Inhibitors sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Tyrosine Kinase Inhibitors, market overview.
Chapter 2: Global Non-Tyrosine Kinase Inhibitors market size in revenue and volume.
Chapter 3: Detailed analysis of Non-Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Tyrosine Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Non-Tyrosine Kinase Inhibitors capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Non-Tyrosine Kinase Inhibitors Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Tyrosine Kinase Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Tyrosine Kinase Inhibitors Overall Market Size
2.1 Global Non-Tyrosine Kinase Inhibitors Market Size: 2022 VS 2029
2.2 Global Non-Tyrosine Kinase Inhibitors Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Non-Tyrosine Kinase Inhibitors Sales: 2018-2029
3 Company Landscape
3.1 Top Non-Tyrosine Kinase Inhibitors Players in Global Market
3.2 Top Global Non-Tyrosine Kinase Inhibitors Companies Ranked by Revenue
3.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Companies
3.4 Global Non-Tyrosine Kinase Inhibitors Sales by Companies
3.5 Global Non-Tyrosine Kinase Inhibitors Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Non-Tyrosine Kinase Inhibitors Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Non-Tyrosine Kinase Inhibitors Product Type
3.8 Tier 1, Tier 2 and Tier 3 Non-Tyrosine Kinase Inhibitors Players in Global Market
3.8.1 List of Global Tier 1 Non-Tyrosine Kinase Inhibitors Companies
3.8.2 List of Global Tier 2 and Tier 3 Non-Tyrosine Kinase Inhibitors Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Non-Tyrosine Kinase Inhibitors Market Size Markets, 2022 & 2029
4.1.2 mTOR Inhibitors
4.1.3 RAF/MEK Inhibitors
4.1.4 CDK Inhibitors
4.2 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue & Forecasts
4.2.1 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2023
4.2.2 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue, 2024-2029
4.2.3 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
4.3 By Type – Global Non-Tyrosine Kinase Inhibitors Sales & Forecasts
4.3.1 By Type – Global Non-Tyrosine Kinase Inhibitors Sales, 2018-2023
4.3.2 By Type – Global Non-Tyrosine Kinase Inhibitors Sales, 2024-2029
4.3.3 By Type – Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
4.4 By Type – Global Non-Tyrosine Kinase Inhibitors Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Non-Tyrosine Kinase Inhibitors Market Size, 2022 & 2029
5.1.2 Liver Cancer
5.1.3 Respiratory Cancer
5.1.4 Brain Cancer
5.1.5 Others
5.2 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue & Forecasts
5.2.1 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2023
5.2.2 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue, 2024-2029
5.2.3 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
5.3 By Application – Global Non-Tyrosine Kinase Inhibitors Sales & Forecasts
5.3.1 By Application – Global Non-Tyrosine Kinase Inhibitors Sales, 2018-2023
5.3.2 By Application – Global Non-Tyrosine Kinase Inhibitors Sales, 2024-2029
5.3.3 By Application – Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
5.4 By Application – Global Non-Tyrosine Kinase Inhibitors Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Non-Tyrosine Kinase Inhibitors Market Size, 2022 & 2029
6.2 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue & Forecasts
6.2.1 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2023
6.2.2 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue, 2024-2029
6.2.3 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
6.3 By Region – Global Non-Tyrosine Kinase Inhibitors Sales & Forecasts
6.3.1 By Region – Global Non-Tyrosine Kinase Inhibitors Sales, 2018-2023
6.3.2 By Region – Global Non-Tyrosine Kinase Inhibitors Sales, 2024-2029
6.3.3 By Region – Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.4.2 By Country – North America Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.4.3 US Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.4.4 Canada Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.4.5 Mexico Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.5.2 By Country – Europe Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.5.3 Germany Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.4 France Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.5 U.K. Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.6 Italy Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.7 Russia Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.8 Nordic Countries Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.9 Benelux Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.6.2 By Region – Asia Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.6.3 China Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.4 Japan Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.5 South Korea Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.6 Southeast Asia Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.7 India Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.7.2 By Country – South America Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.7.3 Brazil Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.7.4 Argentina Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.8.3 Turkey Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8.4 Israel Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8.5 Saudi Arabia Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8.6 UAE Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.1.4 Roche Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.2.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.3.4 Novartis Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Array BioPharma
7.4.1 Array BioPharma Company Summary
7.4.2 Array BioPharma Business Overview
7.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.4.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.4.5 Array BioPharma Key News & Latest Developments
7.5 Nerviano Medical Sciences
7.5.1 Nerviano Medical Sciences Company Summary
7.5.2 Nerviano Medical Sciences Business Overview
7.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.5.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.5.5 Nerviano Medical Sciences Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.6.4 Pfizer Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Merck KGaA
7.7.1 Merck KGaA Company Summary
7.7.2 Merck KGaA Business Overview
7.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.7.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.7.5 Merck KGaA Key News & Latest Developments
7.8 Astex Pharmaceuticals
7.8.1 Astex Pharmaceuticals Company Summary
7.8.2 Astex Pharmaceuticals Business Overview
7.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.8.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.8.5 Astex Pharmaceuticals Key News & Latest Developments
7.9 Cyclacel Pharmaceuticals
7.9.1 Cyclacel Pharmaceuticals Company Summary
7.9.2 Cyclacel Pharmaceuticals Business Overview
7.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.9.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.9.5 Cyclacel Pharmaceuticals Key News & Latest Developments
7.10 Daiichi Sankyo
7.10.1 Daiichi Sankyo Company Summary
7.10.2 Daiichi Sankyo Business Overview
7.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.10.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.10.5 Daiichi Sankyo Key News & Latest Developments
7.11 Onconova Therapeutics
7.11.1 Onconova Therapeutics Company Summary
7.11.2 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Business Overview
7.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.11.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.11.5 Onconova Therapeutics Key News & Latest Developments
7.12 AstraZeneca
7.12.1 AstraZeneca Company Summary
7.12.2 AstraZeneca Non-Tyrosine Kinase Inhibitors Business Overview
7.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.12.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.12.5 AstraZeneca Key News & Latest Developments
7.13 GlaxoSmithKline (GSK)
7.13.1 GlaxoSmithKline (GSK) Company Summary
7.13.2 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Business Overview
7.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.13.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.13.5 GlaxoSmithKline (GSK) Key News & Latest Developments
7.14 Carna Biosciences
7.14.1 Carna Biosciences Company Summary
7.14.2 Carna Biosciences Business Overview
7.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.14.5 Carna Biosciences Key News & Latest Developments
7.15 Celgene Corporation
7.15.1 Celgene Corporation Company Summary
7.15.2 Celgene Corporation Business Overview
7.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.15.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.15.5 Celgene Corporation Key News & Latest Developments
7.16 Eternity Bioscience
7.16.1 Eternity Bioscience Company Summary
7.16.2 Eternity Bioscience Business Overview
7.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.16.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.16.5 Eternity Bioscience Key News & Latest Developments
7.17 Jasco Pharmaceuticals
7.17.1 Jasco Pharmaceuticals Company Summary
7.17.2 Jasco Pharmaceuticals Business Overview
7.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.17.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.17.5 Jasco Pharmaceuticals Key News & Latest Developments
8 Global Non-Tyrosine Kinase Inhibitors Production Capacity, Analysis
8.1 Global Non-Tyrosine Kinase Inhibitors Production Capacity, 2018-2029
8.2 Non-Tyrosine Kinase Inhibitors Production Capacity of Key Manufacturers in Global Market
8.3 Global Non-Tyrosine Kinase Inhibitors Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Non-Tyrosine Kinase Inhibitors Supply Chain Analysis
10.1 Non-Tyrosine Kinase Inhibitors Industry Value Chain
10.2 Non-Tyrosine Kinase Inhibitors Upstream Market
10.3 Non-Tyrosine Kinase Inhibitors Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Non-Tyrosine Kinase Inhibitors Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Non-Tyrosine Kinase Inhibitors in Global Market
Table 2. Top Non-Tyrosine Kinase Inhibitors Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Non-Tyrosine Kinase Inhibitors Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Companies, 2018-2023
Table 5. Global Non-Tyrosine Kinase Inhibitors Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Non-Tyrosine Kinase Inhibitors Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Non-Tyrosine Kinase Inhibitors Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Non-Tyrosine Kinase Inhibitors Product Type
Table 9. List of Global Tier 1 Non-Tyrosine Kinase Inhibitors Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Tyrosine Kinase Inhibitors Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Non-Tyrosine Kinase Inhibitors Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Non-Tyrosine Kinase Inhibitors Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs), 2018-2023
Table 15. By Type - Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs), 2024-2029
Table 16. By Application – Global Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Non-Tyrosine Kinase Inhibitors Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Non-Tyrosine Kinase Inhibitors Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs), 2018-2023
Table 20. By Application - Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs), 2024-2029
Table 21. By Region – Global Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Non-Tyrosine Kinase Inhibitors Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Non-Tyrosine Kinase Inhibitors Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs), 2018-2023
Table 25. By Region - Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs), 2024-2029
Table 26. By Country - North America Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales, (K Pcs), 2024-2029
Table 46. Roche Company Summary
Table 47. Roche Non-Tyrosine Kinase Inhibitors Product Offerings
Table 48. Roche Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Roche Key News & Latest Developments
Table 50. Eli Lilly Company Summary
Table 51. Eli Lilly Non-Tyrosine Kinase Inhibitors Product Offerings
Table 52. Eli Lilly Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Eli Lilly Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Non-Tyrosine Kinase Inhibitors Product Offerings
Table 56. Novartis Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. Array BioPharma Company Summary
Table 59. Array BioPharma Non-Tyrosine Kinase Inhibitors Product Offerings
Table 60. Array BioPharma Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Array BioPharma Key News & Latest Developments
Table 62. Nerviano Medical Sciences Company Summary
Table 63. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Offerings
Table 64. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Nerviano Medical Sciences Key News & Latest Developments
Table 66. Pfizer Company Summary
Table 67. Pfizer Non-Tyrosine Kinase Inhibitors Product Offerings
Table 68. Pfizer Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Pfizer Key News & Latest Developments
Table 70. Merck KGaA Company Summary
Table 71. Merck KGaA Non-Tyrosine Kinase Inhibitors Product Offerings
Table 72. Merck KGaA Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Merck KGaA Key News & Latest Developments
Table 74. Astex Pharmaceuticals Company Summary
Table 75. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Offerings
Table 76. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Astex Pharmaceuticals Key News & Latest Developments
Table 78. Cyclacel Pharmaceuticals Company Summary
Table 79. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Offerings
Table 80. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Cyclacel Pharmaceuticals Key News & Latest Developments
Table 82. Daiichi Sankyo Company Summary
Table 83. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Offerings
Table 84. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Daiichi Sankyo Key News & Latest Developments
Table 86. Onconova Therapeutics Company Summary
Table 87. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Offerings
Table 88. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. Onconova Therapeutics Key News & Latest Developments
Table 90. AstraZeneca Company Summary
Table 91. AstraZeneca Non-Tyrosine Kinase Inhibitors Product Offerings
Table 92. AstraZeneca Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. AstraZeneca Key News & Latest Developments
Table 94. GlaxoSmithKline (GSK) Company Summary
Table 95. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Offerings
Table 96. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 97. GlaxoSmithKline (GSK) Key News & Latest Developments
Table 98. Carna Biosciences Company Summary
Table 99. Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Offerings
Table 100. Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 101. Carna Biosciences Key News & Latest Developments
Table 102. Celgene Corporation Company Summary
Table 103. Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Offerings
Table 104. Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 105. Celgene Corporation Key News & Latest Developments
Table 106. Eternity Bioscience Company Summary
Table 107. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Offerings
Table 108. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 109. Eternity Bioscience Key News & Latest Developments
Table 110. Jasco Pharmaceuticals Company Summary
Table 111. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Offerings
Table 112. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 113. Jasco Pharmaceuticals Key News & Latest Developments
Table 114. Non-Tyrosine Kinase Inhibitors Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 115. Global Non-Tyrosine Kinase Inhibitors Capacity Market Share of Key Manufacturers, 2021-2023
Table 116. Global Non-Tyrosine Kinase Inhibitors Production by Region, 2018-2023 (K Pcs)
Table 117. Global Non-Tyrosine Kinase Inhibitors Production by Region, 2024-2029 (K Pcs)
Table 118. Non-Tyrosine Kinase Inhibitors Market Opportunities & Trends in Global Market
Table 119. Non-Tyrosine Kinase Inhibitors Market Drivers in Global Market
Table 120. Non-Tyrosine Kinase Inhibitors Market Restraints in Global Market
Table 121. Non-Tyrosine Kinase Inhibitors Raw Materials
Table 122. Non-Tyrosine Kinase Inhibitors Raw Materials Suppliers in Global Market
Table 123. Typical Non-Tyrosine Kinase Inhibitors Downstream
Table 124. Non-Tyrosine Kinase Inhibitors Downstream Clients in Global Market
Table 125. Non-Tyrosine Kinase Inhibitors Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Non-Tyrosine Kinase Inhibitors Segment by Type in 2022
Figure 2. Non-Tyrosine Kinase Inhibitors Segment by Application in 2022
Figure 3. Global Non-Tyrosine Kinase Inhibitors Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Tyrosine Kinase Inhibitors Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029 (US$, Mn)
Figure 7. Non-Tyrosine Kinase Inhibitors Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Non-Tyrosine Kinase Inhibitors Revenue in 2022
Figure 9. By Type - Global Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 11. By Type - Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 12. By Type - Global Non-Tyrosine Kinase Inhibitors Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 15. By Application - Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 16. By Application - Global Non-Tyrosine Kinase Inhibitors Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 20. By Region - Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 21. By Country - North America Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 22. By Country - North America Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 23. US Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 28. Germany Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 29. France Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 37. China Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 41. India Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 43. By Country - South America Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 44. Brazil Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
Figure 48. Turkey Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Non-Tyrosine Kinase Inhibitors Revenue, (US$, Mn), 2018-2029
Figure 52. Global Non-Tyrosine Kinase Inhibitors Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Non-Tyrosine Kinase Inhibitors by Region, 2022 VS 2029
Figure 54. Non-Tyrosine Kinase Inhibitors Industry Value Chain
Figure 55. Marketing Channels

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非チロシンキナーゼ阻害剤の世界市場見通し2023年-2029年(Non-Tyrosine Kinase Inhibitors Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

非チロシンキナーゼ阻害剤の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp